MindMed
phase a attention deficit hyperactivity disorder maximizing value through study of various doses and schedules to optimize the drug across indications is a critical and increasingly well studied target in creatively exploring innovative treatment paradigm repeated sub perceptual doses of in seek to demonstrate proof of principle for both the regimen and at home delivery psychiatry paradigms | MindMed
Company
Deck Type
Sector
Industry
Deck date
September 2023
Slide
18 of 32
Similar slides by MindMed
See diffirences between slides (animation)
Investor Presentation
August 2023
phase a attention deficit hyperactivity disorder maximizing value through study of various doses and schedules to optimize the drug across indications is a critical and increasingly well studied target in creatively exploring innovative treatment paradigm repeated sub perceptual doses of in seek to demonstrate proof of principle for both the regimen and at home delivery psychiatry paradigms | MindMed
Related slides by other companies
Bionomics
Investor Presentation
June 2022
is in an ongoing phase prevail study for acute social anxiety disorder compelling rationale for as an acute treatment in social anxiety disorder behavioral task | Bionomics
Other recent decks by MindMed
See all presentations (7 decks)
Results
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Investor Day
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io